Pfizer (PFE) News
NYSE: PFEHealth CareBiotechnology: Pharmaceutical PreparationsUSD
28.28+0.46 (+1.65%)
At close: Oct 9, 4:01 PM ET · Delayed 15 min
PFE news summary
We found 50 recent headlines mentioning Pfizer (PFE): 41 in the past week and 50 in the past 30 days, most often from Nasdaq, Seeking Alpha, Investing.com. For price context, PFE is up 1.65% at $28.28. The most recent story, "Top Research Reports for JPMorgan, ASML & Chevron", was published by Nasdaq on Oct 9, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Pfizer headlines
- Top Research Reports for JPMorgan, ASML & ChevronJPMorgan, ASML and Chevron stand out in today's research, with earnings strength, AI-driven demand and record production shaping their investment outlooks.NasdaqJPM, CVX, ASML, UAVS
- Cancer Stocks to Consider as Oncology Innovation AcceleratesOncology stocks are gaining relevance as cancer care evolves, with Pfizer, Merit Medical Systems and Abbott advancing treatments, diagnostics and screening technologies.NasdaqABT, PFE, MMSI, AZN
- Roche Gets FDA Approval for Another Label Expansion of TecentriqRoche wins FDA approval for Tecentriq in stage III dMMR colon cancer, with trial data showing a 50% lower risk of recurrence or death.Nasdaq
- Dividend Roundup: Starbucks, Pfizer, Micron, AbbVie, and moreSeeking AlphaPFE, ABBV, SBUX
- Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to KnowZacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.Nasdaq
- Pfizer: Previously Bearish, I'm Converting To A Cautious Bull (Rating Upgrade)Seeking Alpha
- Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?Key PointsBristol Myers Squibb maintains a robust portfolio in oncology and hematology with a focus on specialized treatments.NasdaqBMY, PFE
- 2 Growth Stocks to Buy in OctoberKey PointsGrail’s stock could skyrocket if the FDA approves Galleri.NasdaqMRK, LLY, PFE, VEEV
- NVS Wins FDA Nod for Label Expansion of Immunology Drug RhapsidoNovartis wins FDA approval for Rhapsido in symptomatic dermographism, expanding its chronic hives opportunity as pipeline setbacks raise pressure for growth.NasdaqNVS, PFE
- Will Pfizer (PFE) Beat Estimates Again in Its Next Earnings Report?Pfizer (PFE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.Nasdaq
- Pfizer's Oncology Outlook: Key Drivers to Watch Ahead of Q3 ResultsPFE's oncology growth in Q3 hinges on key drug sales, biosimilars and progress across a late-stage pipeline.NasdaqPFE, AZN, JNJ, MRK
- FDA Backs PFE's Tukysa Combo in Front-Line Maintenance Breast CancerPfizer's Tukysa combo regimen wins FDA approval for frontline maintenance breast cancer treatment, extending its use beyond the second-line setting.NasdaqPFE, INO
- Pfizer Trades Under 10 Times Forward Earnings With a Yield Near 6%. Here's What History Says Happens Next.Key PointsPfizer has existed for more than 100 years.NasdaqPFE, LLY
- These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your RadarWhy investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.NasdaqPFE, JNJ
- How Is Eli Lilly's Oncology Portfolio Poised Ahead of Q3 Earnings?LLY's oncology portfolio is poised for growth as Jaypirca, Inluriyo and Retevmo may offset slower Verzenio sales and mature-drug declines.NasdaqLLY, AZN, PFE, MRK
- Pfizer to close penicillin unit, cut around 330 jobs in ItalySeeking Alpha
- Pfizer to cut around 330 jobs in Italy, unions sayInvesting.com
- FDA Approves Pfizer's TUKYSA Regimen For Front-Line HER2+ Breast Cancer Maintenance(RTTNews) - Pfizer Inc. (PFE) announced that the U.S. Food and Drug Administration (FDA) approved TUKYSA in combination with trastuzumab and pertuzumab for maintenance treatment of adults with…NasdaqPFE, BRK.A
- Pfizer's TUKYSA Gets FDA Nod For Front-Line HER2+ Breast Cancer Maintenance(RTTNews) - Pfizer Inc. (PFE) announced that the U.S. Food and Drug Administration (FDA) approved TUKYSA in combination with trastuzumab and pertuzumab for maintenance treatment of adults with…Nasdaq
- Pfizer Stock: Buy, Sell, or Hold?Key PointsPfizer is racing towards important patent cliffs.Nasdaq
- Stocks Settle Lower on Higher Bond YieldsThe S&P 500 Index ($SPX ) (SPY ) closed down by -0.22% on Wednesday, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed down by -0.66%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down…NasdaqMSTR, DE, RARE, ADI
- Pfizer’s Tukysa regimen approved in U.S. for front-line breast cancerSeeking Alpha
- Warren Buffett's Favorite Valuation Indicator Blew Past the Level He Warned Was "Playing With Fire." Here Are 3 Stocks Still Cheap Enough to Buy.Key PointsEnterprise Products Partners benefits from the driving force behind the stock market boom.NasdaqPFE, JPM, EPD
- 3 of the Best Dividend Stocks to Buy in October 2026Key PointsThe stocks listed below pay more than double what the average S&P 500 stock yields.NasdaqPFE, XOM, O
- Daily Dividend Report: PFE,WS,LW,MMSPfizer today announced that its board of directors declared a $0.43 fourth-quarter 2026 dividend on the company's common stock, payable December 7, 2026, to holders of the Common Stock of record at…NasdaqPFE, WS, LW, MMS
- Pfizer Declares $0.43 Fourth-Quarter Dividend For Shareholders(RTTNews) - Pfizer Inc. (PFE) announced that its Board of Directors has declared a fourth-quarter 2026 cash dividend of $0.43 per share on the company's common stock.Nasdaq
- PFE vs. JNJ: Which Stock Is the Better Value Option?PFE vs. JNJ: Which Stock Is the Better Value Option?NasdaqPFE, JNJ
- AbbVie's Epcoritamab Combo Shows PFS Benefit in Frontline DLBCLABBV's epcoritamab plus R-CHOP cut progression or death risk by 51% in frontline DLBCL, meeting the phase III study's PFS goal.NasdaqABBV, GMAB, PFE, FRO
- Are Investors Undervaluing Pfizer (PFE) Right Now?Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the…Nasdaq
- Why Pfizer Might Be the Most Underrated Dividend Stock to Buy Right NowKey PointsPfizer's stock has been struggling for multiple years, and it trades at a low valuation.Nasdaq
- Pfizer vs. J&J: Comparing Growth, Patent Risks and ValuationJ&J's diversified portfolio, new drug launches and sales growth give it an edge despite Pfizer's cheaper valuation and higher yield.NasdaqJNJ, PFE, NVO, LLY
- SMMT Inks Deal With AZN-Daiichi to Study Ivonescimab + Datroway CombosSummit is teaming up with AstraZeneca and Daiichi to test ivonescimab with Datroway across breast and lung cancers, broadening its potential.NasdaqSMMT, AZN, PFE
- Vaxcyte Catapults After Going Toe-To-Toe With Pfizer, Merck In Vaccine StudyVaxcyte stock catapulted Monday after its experimental pneumococcal vaccine proved it's not inferior to marketed shots from Pfizer and Merck. The post Vaxcyte Catapults After Going Toe-To-Toe With…Investor's Business DailyPCVX, PFE
- Eli Lilly vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?Key PointsEli Lilly's dominance in metabolic health through blockbuster weight-loss drugs.NasdaqLLY, PFE
- Got $10,000 to Invest in October? These Stocks Could Generate Over $634 in Annual Income.Key PointsEnergy Transfer is a midstream leader with an especially juicy distribution.NasdaqVZ, PFE
- Better High-Yield Dividend Stock: Pfizer or Novo Nordisk?Key PointsNovo Nordisk is a leading GLP-1 company, but its portfolio beyond that is limited.NasdaqPFE, NVO, LLY
- 3 Dirt Cheap Dividend Stocks Worth Buying in OctoberKey PointsPfizer is getting back on its feet after a difficult post-pandemic stretch.NasdaqPFE, BMY, UNH
- My 3 Favorite Ultra-High-Yield Dividend Stocks to Buy for OctoberKey PointsAres Capital could make more money as interest rates increase.NasdaqPFE, EPD, ARCC
- AbbVie, Amgen, Pfizer, GSK among participants in new 340B rebate pilotSeeking AlphaAMGN, ABBV, PFE
- 3 Income Stocks Under $30 That Yield More Than the 10-Year Treasury NoteThe 10-year Treasury note yielded around 5.3% in late September. One month before, it was around 4.78%, and it's up by more than a full percentage point from where it was one year ago. To put that…NasdaqPFE, LLY, ABBV, MRK
- Bristol Myers Squibb Now Trades at Only 9.4X Forward Earnings -- Is This Value Stock a Buy?Key PointsBristol Myers has faced patent cliffs in recent years, and there are more on the horizon.NasdaqBMY, PFE, BNTX
- After Hours Most Active for Oct 2, 2026 : GRAB, WBD, NKE, WMT, F, NVDA, NEE, GME, QQQ, EXC, PFE, SOThe NASDAQ 100 After Hours Indicator is down -10.55 to 30,797.38. The total After hours volume is currently 150,344,592 shares traded.The following are the most active stocks for the after hours…NasdaqGRAB, NKE, WMT, F
- Novo Nordisk vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?Key PointsNovo Nordisk maintains high profitability through its specialization in chronic disease management and metabolic health.NasdaqNVO, PFE
- Kevin Warsh's Inflation Stance Makes These Cheap Dividend Stocks Look a Lot More AttractiveKey PointsKevin Warsh has stated that inflation is the Fed's primary target right now.NasdaqMDT, PFE
- Noteworthy ETF Outflows: PRF, CVX, BAC, PFELooking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Invesco RAFI US 1000 ETF (Symbol: PRF) where we have detected an…NasdaqPRF, CVX, BAC, PFE
- Lilly vs. Novo: Inside the Milan EASD Showdown and the ETFs Poised to WinLLY and Novo face off at EASD as new data fuels the GLP-1 market, while ETFs offer diversified exposure to weight loss drug growth.NasdaqREGN, PFE, NVO, LLY
- Moderna vs. BioNTech: Which mRNA Stock Is the Better Buy Now?MRNA's respiratory vaccine expansion and promising oncology results offer potential growth as COVID-19 demand normalizes.NasdaqMRNA, BNTX, PFE, MRK
- After Hours Most Active for Sep 29, 2026 : SHV, NU, GRAB, RIG, NEOG, IXUS, NVDA, WMT, PFE, AG, EXC, BMNRThe NASDAQ 100 After Hours Indicator is up 45.01 to 30,384.34. The total After hours volume is currently 147,682,851 shares traded.The following are the most active stocks for the after hours…NasdaqSHV, NU, GRAB, RIG
- Summit Shares Jump on $2B Strategic Investment From AstraZenecaSMMT shares jump as AstraZeneca commits $2 billion to accelerate ivonescimab development and expand clinical collaboration.NasdaqSMMT, AZN, PFE
- Pfizer: Growth Portfolio And Cost Cuts Support A Buy Through The LOE TroughSeeking Alpha